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Using Procalcitonin to Guide Antibiotic Therapy
Chanu Rhee1,2
1Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, Massachusetts; 2Division of Infectious Diseases, Brigham and Women’s Hospital, 
Boston, Massachusetts
Procalcitonin levels rise in response to systemic inflammation, especially of bacterial origin. Multiple randomized controlled trials 
have demonstrated that procalcitonin-based algorithms can safely reduce antibiotic use in 2 clinical scenarios. First, in stable, low-
risk patients with respiratory infections, procalcitonin levels of <0.25 µg/L can guide the decision to withhold antibiotics or stop 
therapy early. Second, in critically ill patients with suspected sepsis, clinicians should not initially withhold antibiotics, but procal-
citonin levels of <0.5 µg/L or levels that decrease by ≥80% from peak can guide discontinuation once patients stabilize. The recent 
stop antibiotics on procalcitonin guidance study (SAPS), the largest procalcitonin trial to date, demonstrated reduction in both 
antibiotic exposure and mortality in critically ill patients. Although procalcitonin is ready for routine use, future research should 
examine optimal strategies for implementation in hospitals, its real-world impact on clinical outcomes and costs, its applicability to 
immunocompromised patients, and the generalizability of trials to the US population.
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Up to 30%–50% of antibiotics given to hospitalized patients may 
be unnecessary [1]. Treatment courses commonly exceed rec-
ommended durations or are targeted towards colonizing or con-
taminating microorganisms [2]. Antibiotic overprescription has 
fueled the emergence of antibiotic-resistant bacteria as well as 
unnecessary drug adverse events and propagation of Clostridium 
difficile infection [3]. This global public health threat has stimu-
lated national calls for hospitals to improve antibiotic prescrib-
ing practices and implement stewardship programs. However, 
in the face of imperfect diagnostic tools, clinicians are reluctant 
to withhold antibiotics when infection is suspected. This pres-
sure is compounded by national quality measures compelling 
clinicians to immediately start antibiotics in potentially septic 
patients, even when the diagnosis is uncertain [4]. Subsequent 
antibiotic de-escalation can be challenging because 40% or more 
of patients with sepsis never have a pathogen identified [5].
Additional tools to help guide antibiotic prescribing are thus 
sorely needed. Biomarkers of bacterial infection are attractive 
because they can provide objective data to augment clinicians’ 
intuition in starting, withholding, or stopping antibiotics. Of 
the various biomarkers, procalcitonin has been the most exten-
sively studied. This review will focus on the literature supporting 
procalcitonin’s utility as a biomarker of bacterial infection and 
its role in guiding antibiotic therapy in adult patients.
PROCALCITONIN AS A BIOMARKER FOR BACTERIAL 
INFECTION AND SEPSIS
Procalcitonin is a precursor hormone of calcitonin that 
is undetectable in healthy states, but it is upregulated by 
cytokines released in response to bacterial infections [6, 7]. 
Conversely, procalcitonin production is blocked by interfer-
on-gamma, a cytokine released in response to viral infections 
[8]. Procalcitonin has been used in Europe for many years and 
was also approved for use in the United States by the US Food 
and Drug Administration (FDA) as a diagnostic aid for sepsis 
in 2005. It also gained an FDA indication in 2016 for serial use 
to assess sepsis progression and 28-day mortality risk. Several 
different procalcitonin assays exist, but all demonstrate good 
concordance at clinically relevant cutoffs [9].
Serum procalcitonin levels rise rapidly in response to sys-
temic inflammatory insults, with peak levels that correlate with 
the intensity of the stimulus. Procalcitonin has a short half-life 
(25–30 hours), and levels decline rapidly with resolution of 
inflammation [6, 10]. These properties make it potentially use-
ful in helping decide whether to start antibiotics and when to 
stop antibiotics in a clinically improving patient. The kinetics 
also explain the prognostic value of both the initial procalci-
tonin level and subsequent trends [11]. The nonbinary nature of 
the test also means that different procalcitonin thresholds differ 
in their sensitivity and specificity, while allowing for potential 
variation in algorithms used to guide antibiotic therapy.
Although procalcitonin is more specific for bacterial infec-
tions than other inflammatory markers such as C-reactive pro-
tein [12], false positives can occur. Major stressors that cause 
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systemic inflammation, such as severe trauma, circulatory 
shock, surgery, burns, inhalation injury, and pancreatitis, can 
also elevate procalcitonin levels, possibly through gut translo-
cation of lipopolysaccharide or other bacterial products [13]. 
False negatives can also occur, notably in contained localized 
infections such as mediastinitis, empyema, or abscesses, or if 
procalcitonin is drawn too early in the course of infection [14].
The performance of procalcitonin as a diagnostic biomarker 
for sepsis in intensive care unit (ICU) patients has been exam-
ined in several studies and summarized in a recent meta-anal-
ysis by Wacker et al [15]. This meta-analysis pooled 30 studies, 
with a total of 3244 patients, and found moderate accuracy 
(overall sensitivity of 77% and specificity of 79%), with sub-
stantial heterogeneity between studies. However, procalcitonin 
levels are significantly higher in culture-positive sepsis versus 
culture negative-sepsis, and thus diagnostic performance may 
be better in the former group of patients [5, 16]. Furthermore, 
in critically ill patients with microbiologically documented 
infection, procalcitonin levels differ by site of infection, with the 
highest levels in those with positive blood cultures and lowest 
with pulmonary cultures [17]. Unfortunately, it is in the sep-
tic patients where no organism is identified that accurate bio-
markers of infection would be most clinically helpful. Attempts 
to characterize the accuracy of procalcitonin in these patients 
are hampered by the lack of a true gold standard for diagnos-
ing sepsis, because even experienced clinicians often disagree 
on whether or not patients were septic in retrospect [18]. It is 
similarly impossible to characterize procalcitonin’s accuracy in 
pneumonia, because the absence of positive cultures does not 
rule out bacterial infection or coinfection when viral pathogens 
are identified.
Because of the lack of a reliable reference standard for iden-
tifying bacterial pneumonia and sepsis, particularly in cul-
ture-negative patients, the utility of procalcitonin cannot be 
determined through observational studies alone. However, 
numerous randomized intervention studies have examined 
whether procalcitonin-based algorithms can help clinicians 
decide whether to start or stop antibiotic therapy, without 
adversely impacting patients through delayed antibiotic therapy 
or inadequate treatment courses. These studies have primarily 
demonstrated efficacy in 2 clinical scenarios: adult patients 
with suspected respiratory infections, and critically ill adults 
with any type of suspected infection. Improving antibiotic use 
in these 2 clinical scenarios carries the potential for significant 
benefit given that respiratory infections are the most common 
indication for antibiotics in hospitalized patients and antibiotic 
use is most prevalent in ICUs [19].
PROCALCITONIN TO GUIDE ANTIBIOTIC THERAPY 
FOR RESPIRATORY INFECTIONS
Randomized controlled trials that have shown that procalci-
tonin guidance can help safely decrease antibiotic exposure in 
patients with suspected or proven respiratory infections are 
summarized in Table 1. Christ-Crain et al [20] first demon-
strated this in a single hospital in Switzerland in patients 
who presented to the emergency department with suspected 
lower respiratory tract infections. Procalcitonin was used 
to help determine whether not to initiate antibiotics, with a 
cutoff threshold of 0.25 µg/L. The procalcitonin group had 
a 47% reduced rate of antibiotic exposure, with no differ-
ence in laboratory or clinical outcomes. Follow-up trials in 
the same hospital, using similar procalcitonin algorithms, 
demonstrated efficacy in safely reducing antibiotic exposure 
in patients hospitalized for suspected community-acquired 
pneumonia and exacerbations of chronic obstructive pulmo-
nary disease [21, 22].
The largest study to date examining procalcitonin for res-
piratory infections, the Procalcitonin Guided Antibiotic 
Therapy and Hospitalisation in Patients With Lower 
Respiratory Tract Infections (ProHOSP) study, was a multi-
center randomized controlled trial involving 1359 adults at 
6 hospitals in Switzerland who presented to the emergency 
department with any type of suspected respiratory tract 
infection [23]. Investigators in this study tested the utility of 
procalcitonin to inform both treatment initiation as well as 
discontinuation. As in prior studies, clinicians were encour-
aged to withhold antibiotics for patients with procalcitonin 
values of ≤0.25 µg/L. The study then required repeat procal-
citonin testing on days 3, 5, 7, and at discharge. The investiga-
tors also recommended stopping antibiotics if procalcitonin 
levels decreased by ≥80% when the initial procalcitonin was 
>5–10 µg/L. Clinicians were allowed to overrule the algorithm 
and start antibiotics in patients with respiratory or hemody-
namic instability, pneumonia due to Legionella pneumophila, 
or other risk factors for poor outcomes regardless of procalci-
tonin level. The procalcitonin group had a significantly lower 
mean duration of antibiotics (5.7 vs 8.7 days), with no differ-
ence in adverse events (including death, ICU admission, and 
recurrent infection). The procalcitonin algorithm also safely 
facilitated earlier antibiotic discontinuation in the subgroup 
of patients with confirmed community-acquired pneumonia, 
including those with documented bacteremia. Overall, 75% of 
patients in the procalcitonin group received any antibiotics, 
vs 88% in the control group. The algorithm was overruled by 
the physician based on their clinical judgment in only 9.2% 
of cases.
Although the trials studying procalcitonin for respiratory 
infections have generally focused on patients presenting to the 
emergency room (or in some cases the outpatient setting [24, 
25]), one study demonstrated efficacy of procalcitonin in safely 
guiding antibiotic discontinuation in ICU patients with ven-
tilator-associated pneumonia [26]. A  subsequent Cochrane 
review concluded that procalcitonin guidance for respiratory 
patients in a variety of settings (including the emergency 
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Table 1. Procalcitonin Randomized Controlled Trials for Respiratory Tract Infections in Adult Patients
First Author 
(Year)
[Reference]
Trial Name
Setting
(Country)
Number and Type 
of Infection PCT Algorithm Exclusion Criteria
Antibiotic 
Reduction 
Outcomes Clinical Outcomes
Christ-Crain 
(2004) [20]
1 hospital 
(Switzerland)
243 patients with 
LRTI
Initiation only: antibiotics strongly 
discouraged (<0.1 µg/L), 
discouraged (0.1–0.25), 
encouraged (0.25–0.5), strongly 
encouraged (≥0.5). Repeat PCT 
after 6–24 hours if antibiotics 
withheld
Severely immunocom-
promised, cystic 
fibrosis, active tubercu-
losis, hospital-acquired 
pneumonia
47% reduction in 
antibiotic use 
(P < .0001)
No difference (including hospital 
mortality or long- 
term mortality at mean 
5.3 months, hospital or ICU 
LOS, laboratory outcomes)
Christ-Crain 
(2006) [21]
ProCAP
1 hospital 
(Switzerland)
302 patients with 
CAP
Initiation and Discontinuation: 
antibiotics strongly discouraged 
(<0.1 µg/L), discouraged (0.1–
0.25), encouraged (0.25–0.5), 
strongly encouraged (≥0.5). 
Repeat PCT after 6–24 hours if 
antibiotics withheld, and at days 
4, 6, and 8
Severely immunocom-
promised, cystic 
fibrosis, active tubercu-
losis, hospital-acquired 
pneumonia
52% relative risk 
of antibiotic 
exposure 
and median 
5 vs 12 days 
of antibiotic 
treatment (P < 
.001 for both)
No difference (including 
mortality, ICU admission, 
treatment success, laboratory 
outcomes)
Stolz
(2007) [22]
1 hospital 
(Switzerland)
208 patients 
with COPD 
exacerbation
Initiation only: antibiotics discour-
aged (<0.1 µg/L), discouraged 
if clinically stable (0.1–0.25), 
encouraged (>0.25). Repeat 
PCT after 6–24 hours if antibiot-
ics withheld
Immunosuppression, 
asthma, cystic fibrosis, 
infiltrates on chest 
radiograph, psychiatric 
illness
56% relative risk 
of antibiotic 
exposure; 
40% vs 
72% overall 
antibiotic use 
(P < .0001 for 
both)
No difference (including death, 
treatment success, hospital 
LOS, ICU admission, improve-
ment in FEV1 at 14 days and 
6 months, 6 month rehospital-
ization rate, mean time to next 
exacerbation)
Briel (2008) 
[25]
53 outpatient 
physicians in 
(Switzerland)
458 outpatients 
with acute 
respiratory 
tract infections
Initiation and Discontinuation: 
antibiotics strongly discour-
aged (≤0.1 µg/L), discouraged 
(0.1–0.25), encouraged (>0.25). 
Repeat PCT after 6–24 hours if 
antibiotics withheld
Antibiotics within prior 
28 days, psychiatric 
disorders, severe 
immunosuppres-
sion, cystic fibrosis, 
active tuberculosis, 
need for immediate 
hospitalization
72% decrease 
in antibiotic 
use (95% CI, 
66%–78%)
No difference in activity restric-
tion at 14 days, or ongoing 
symptoms or relapsing infec-
tion at 28 days
Kristoffersen 
(2009) [45]
3 hospitals 
(Denmark)
223 patients with 
LRTI
Initiation only: antibiotics discour-
aged (<0.25 µg/L), encour-
aged (0.25–0.5), and strongly 
encouraged (≥0.5). Single PCT 
measurement
None described Mean 5.1 vs 
6.8 days of 
antibiotic ther-
apy (P = .007)
No difference (including hospital 
LOS, ICU admission, hospital 
mortality)
Schuetz 
(2009) [23]
ProHOSP
6 hospitals 
(Switzerland)
1359 patients 
with LRTI
Initiation and Discontinuation: 
antibiotics strongly discouraged 
(≤0.1 µg/L), discouraged (0.1–
0.25), encouraged (0.25–0.5), 
strongly encouraged (≥0.5). 
Repeat PCT after 6–24 hours if 
antibiotics withheld, and at days 
3, 5, 7, and discharge
Active intravenous drug 
use, severe immuno-
suppression, life-threat-
ening comorbidities, 
hospital-acquired 
pneumonia, chronic 
infection requiring 
antibiotics
Mean 5.7 vs 
8.7 days of 
antibiotic 
therapy (rela-
tive change, 
−34.8%; 95% 
CI, −40.3% to 
−28.7%)
No difference (composite of 
30-day adverse outcomes 
including death, ICU admis-
sion, and disease-specific 
complications, and recurrent 
LRTI); less frequent antibiot-
ic-associated adverse events 
(19.8% vs 28.1%)
Burkhardt 
(2010) [24]
15 primary care 
practices 
(Germany)
550 patients with 
mild respi-
ratory tract 
infection
Initiation only: no antibiotics 
(<0.25 µg/L) or yes antibiotics 
(≥0.25)
Recent antibiotics, 
chronic liver disease, 
recent major surgery, 
autoimmune or 
systemic inflammatory 
disorders, dialysis, 
medullary C-cell 
carcinoma
21.5% vs 36.7% 
of patients 
received 
antibiotics
No difference in significant 
health impairment after 
14 days
Long
(2011) [46]
1 hospital 
(China)
172 patients with 
low- 
risk CAP 
(discharged 
from ED)
Initiation only: antibiotics strongly 
discouraged (≤0.1 µg/L), dis-
couraged (0.1–0.25), encour-
aged (>0.25). Repeat PCT 
after 6–12 hours if antibiotics 
withheld
Pregnancy, antibiotics 
started ≥48 hours 
before enrollment, 
immunocompro-
mised, withholding 
of life-support, active 
tuberculosis
55% relative risk 
of antibiotic 
exposure 
(P = .003); 
median 5 vs 
7 days of antibi-
otic treatment 
(P < .001)
No difference (all survived at 4 
weeks, with similar clinical 
and laboratory outcomes)
Tang
(2013) [47]
1 hospital
(China)
225 patients 
with asthma 
exacerbation
Initiation only: antibiotics strongly 
discouraged (≤0.1 µg/L), dis-
couraged (0.1–0.25), encour-
aged (>0.25). Repeat PCT after 
6–8 hours if initial PCT <0.25
Recent antibiotics, other 
bacterial infections, 
pneumonia on chest 
radiograph, other chronic 
respiratory disease, 
severe organ dysfunction
46.1% vs 74.8% 
of patients 
received 
antibiotics (P < 
.001)
No difference (including asthma 
control, secondary ED visits, 
hospital readmission, addi-
tional steroids or antibiotics, 
FEV1)
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department, ICU, and primary care settings) resulted in a sig-
nificant reduction in total antibiotic exposure (median 4 days 
vs 8 days), with no difference in mortality or rates of treatment 
failure [27].
PROCALCITONIN TO GUIDE ANTIBIOTIC THERAPY IN 
CRITICALLY ILL PATIENTS
Compared with stable patients with respiratory infections, 
it is less realistic that clinicians will withhold antibiotics in 
critically ill patients with suspected infection, regardless of 
procalcitonin results. This is reasonable in light of the imper-
fect sensitivity of procalcitonin for bacterial sepsis, and the 
potential to miss severe infections if only looking at a sin-
gle measurement taken early in the course of disease. Thus, 
in randomized controlled trials examining the ICU patient 
population (summarized in Table  2), procalcitonin has gen-
erally been used as an aid to discontinue therapy after clin-
ical stabilization. Procalcitonin cutoffs to stop antibiotics in 
ICU patients have been higher (0.5  µg/L, or even greater in 
some studies) than cutoffs used for stable patients with res-
piratory tract infections (0.25 µg/L). Small, single-center stud-
ies in medical-surgical or surgical ICUs in Switzerland and 
Germany first demonstrated that procalcitonin used in this 
manner could safely reduce antibiotic therapy in patients with 
suspected sepsis [17, 28, 29].
The first large multicenter study, the PROcalcitonin to Reduce 
Antibiotic Treatments in Acutely ill patients (PRORATA) trial, 
was conducted in 5 academic hospitals in France and included 
621 adult patients with suspected bacterial infection at admis-
sion or during their stay in the ICU [30]. This study was unique 
in the ICU-based trials in that the algorithm included an ini-
tial procalcitonin to help assess whether to start antibiotics in 
addition to subsequent daily procalcitonin levels to help decide 
when to stop antibiotics. The cutoff procalcitonin value for dis-
continuation was <0.5 µg/L or a decrease from peak value by 
≥80%. Overall, more than 80% of patients were retrospectively 
adjudicated to have microbiologically or clinically documented 
infection. The procalcitonin group had significantly more days 
at 28 days without antibiotics (14.3 days vs 11.6 days) and an 
overall 23% relative reduction in days of antibiotic exposure 
(mean 10.3 vs 13.3 days). The algorithm was overruled in 53% 
of cases (a much higher rate than in ProHOSP). The most com-
mon reason for nonadherence was physician reluctance in stop-
ping antibiotic therapy in patients with low procalcitonin levels 
but ongoing clinical instability. The study showed noninferior-
ity for 28-day and 60-day mortality, with no difference in other 
clinical outcomes. However, many critics were concerned about 
the trend towards higher 60-day mortality seen in the procalci-
tonin group (30.0% vs 26.1%), even though it did not meet the 
10% noninferiority boundary set by the trial. Although none 
of the 60-day deaths in the procalcitonin group appeared to be 
attributable to relapsed or recurrent infection, this finding has 
made some critical care clinicians reticent to use procalcitonin 
in this way.
The next multicenter randomized controlled trial, the 
ProGUARD study, was conducted in 11 Australian ICUs and 
enrolled 400 adult patients with suspected sepsis [31]. The algo-
rithm was much more conservative than PRORATA, because it 
advised stopping antibiotics if procalcitonin was <0.1 µg/L or 
levels decreased by >90% from baseline (vs 0.5 µg/L or ≥80% 
decline in PRORATA). The control arm explicitly included 
antimicrobial stewardship guidance. There was a nonsignifi-
cant trend towards decreased antibiotic use in the procalcitonin 
group (median treatment duration of 9 vs 11 days, P = .58), with 
no difference in clinical outcomes, despite high (>97%) proto-
col compliance. The more conservative procalcitonin threshold 
used may explain the lack of benefit compared with PRORATA. 
In addition, the study was likely underpowered because it was 
designed to detect an ambitious reduction of antibiotic therapy 
by 3.75 days.
The largest trial to date was the Stop Antibiotics on 
Procalcitonin guidance Study (SAPS), a multicenter rand-
omized trial in patients with suspected infection admitted 
to the ICU in 3 university medical centers and 12 teaching 
First Author 
(Year)
[Reference]
Trial Name
Setting
(Country)
Number and Type 
of Infection PCT Algorithm Exclusion Criteria
Antibiotic 
Reduction 
Outcomes Clinical Outcomes
Branche 
(2015) [48]
1 hospital 
(United 
States)
300 patients with 
nonpneumonic 
LRTI
Initiation only: antibiotics strongly 
discouraged (≤0.1 µg/L), 
discouraged (0.1–0.25), 
encouraged (0.25–0.5), strongly 
encouraged (≥0.5). PCT inter-
vention arm coupled with viral 
PCR testing.
Definitive infiltrates on 
chest radiograph, 
immunosuppression, 
hypotension, ICU 
requirement, ≥15% 
peripheral bands, 
conditions known to 
increase PCT, antibiot-
ics before admission
No difference 
overall, but 
less antibi-
otics in algo-
rithm-adherent 
patients (2.0 
vs 4.0 days; 
P = .004)
No difference in adverse events 
(no deaths in either arm; same 
median hospital LOS and 
number of posthospitalization 
healthcare visits)
Abbreviations: CAP, community-acquired pneumonia; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ED, emergency department; FEV1, forced expiratory volume 
at 1 second; ICU, intensive care unit; LOS, length of stay; LRTI, lower respiratory tract illness; PCR, polymerase chain reaction; PCT, procalcitonin. 
Table 1. Continued
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Table 2. Procalcitonin Randomized Controlled Trials for Infections in Critically Ill Adult Patients
First Author 
(Year) 
[Reference]
Trial Name
Setting
(Country)
Number and Type of 
Infection PCT Algorithm Exclusion Criteria
Antibiotic 
Reduction 
Outcomes Clinical Outcomes
Nobre (2008)  
[17]
1 Medical-Surgical 
ICU (Switzerland)
79 patients with 
severe sepsis/sep-
tic shock
Discontinuation only: 
stop antibiotics if 
PCT decreased 
90% from initial 
value, but not 
before day 3 (if 
baseline <1 µg/L) 
or day 5 (if baseline 
≥1)
Organisms or conditions 
requiring prolonged 
duration of therapy, severe 
viral or parasitic infections, 
antibiotics started ≥48 
hours before enrollment, 
severely immunocompro-
mised, withholding of life 
support
4 day reduction in 
median duration 
of antibiotic ther-
apy (P = .003)
No different in mortality 
and recurrent infection; 
reduced ICU LOS by 
2 days (P = .03)
Hochreiter  
(2009) [28]
1 Surgical ICU 
(Germany)
110 patients with 
suspected or con-
firmed sepsis
Discontinuation only: 
stop antibiotics 
if PCT <1 µg/L 
or decrease to 
25%–35% of initial 
value over 3 days
Antibiotics started before 
ICU admission, therapy 
limitation due to goals 
of care
Mean 5.9 vs 
7.9 days (P < 
.001)
No difference (treatment 
success, ICU LOS, 
SOFA score, hospital 
mortality)
Schroeder  
(2009) [29]
1 Surgical ICU 
(Germany)
27 patients with 
severe sepsis
Discontinuation only: 
stop antibiotics 
if PCT <1 µg/L or 
decrease to <35% 
of initial value over 
3 days
Antibiotics started before 
ICU admission
Mean 6.6 vs 
8.3 days (P < 
.001)
No difference (SAPS II or 
SOFA score, ICU stay, 
hospital mortality)
Stolz (2009) [26]
ProVAP
7 ICUs in 3 hospitals 
(Switzerland, 
United States)
101 patients with ven-
tilator-associated 
pneumonia
Discontinuation only: 
after 72 hours, 
antibiotic cessation 
strongly encour-
aged (<0.25 µg/L), 
encouraged (0.25–
0.5 or decrease 
by ≥80%), 
discouraged (≥0.5 
or decrease by 
<80%), strongly 
discouraged (>1)
Pregnant, enrolled in another 
trial, immunosuppressed, 
coexisting extrapulmonary 
infection requiring antibiot-
ics for >3 days
13 vs 9.5 antibiot-
ic-free days alive 
28 days after 
ventilator-associ-
ated pneumonia 
onset (overall 
27% reduction 
in antibiotic ther-
apy, P = .038)
No difference (mechanical 
ventilation-free days, 
ICU-free days alive, 
hospital LOS, 28-day 
mortality)
Boudama (2010) 
[30]
PRORATA
5 medical ICUs and 
2 surgical ICUs 
(France)
621 patients with 
suspected infection
Initiation and 
Discontinuation: 
antibiotics strongly 
discouraged 
(<0.25 µg/L), 
discouraged (0.25–
0.5), encouraged 
(0.5–1), strongly 
encouraged 
(≥1) (daily PCT 
measurements). 
Discontinuation 
also if PCT 
decreased ≥80% 
from peak
Pregnancy, bone marrow 
transplant, or neutrope-
nic, infections requiring 
long-term antibiotics, poor 
chance of survival, and 
do-not-resuscitate orders
Mean 11.6 vs 
14.3 days of 
therapy (P < 
.0001)
No difference in noninfe-
riority analysis (28-day 
and 60-day mortality), 
but trend towards 
increased 60-day mor-
tality (+3.8%). No differ-
ence in infection relapse 
or superinfection, 
mechanical ventilation, 
ICU and hospital LOS
Annane (2013) 
[49]
8 ICUs (France) 58 patients with 
culture-negative 
severe sepsis
Initiation and 
Discontinuation:
withhold or stop 
antibiotics 
(<0.25 µg/L); 
antibiotics strongly 
discouraged 
(0.25–0.5), recom-
mended (0.5–5), 
strongly recom-
mended (≥0.5). 
Higher cutoffs 
used for postsurgi-
cal patients
Pregnancy, severe burns, 
trauma, cardiac arrest, 
postorthopedic surgery, 
neutropenic, withholding 
of life-supportive thera-
pies, indisputable clinical 
infection, antibiotic expo-
sure ≥48 hours before ICU 
admission
Nonsignificant 
trend: 67% vs 
81% of patients 
on antibiotics at 
day 5 (P = .24)
No difference in day 5 mor-
tality, ICU or hospital 
LOS or mortality, SOFA 
score at day 3 or 5 (but 
study terminated early 
due to low incidence of 
eligible patients)
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hospitals [32]. Importantly, this trial was conducted in the 
Netherlands, a country known to have judicious antibiotic 
prescribing practices. Baseline procalcitonin measurements 
were obtained around time of initiation of antibiotics and 
each day until ICU discharge or 3 days after systemic anti-
biotics were stopped. The algorithm in SAPS was similar to 
PRORATA, as clinicians were advised to stop antibiotics if 
procalcitonin was ≤0.5 µg/L or if it decreased by ≥80% of peak 
value. Unlike PRORATA, the algorithm was not designed to 
encourage or discourage antibiotic initiation at the time of 
suspected infection.
Overall, the procalcitonin group had significantly lower 
median antibiotic consumption: 7.5 vs 9.3 defined daily doses 
and 5 vs 7 median days of treatment. As expected in this country 
with low antibiotic prescribing rates, treatment durations were 
lower in both arms compared with ProGUARD and PRORATA. 
Although this was designed as a noninferiority study, the pro-
calcitonin group had statistically significant lower mortality at 
28 days (20% vs 25% in control group, P = .0122) and at 1 year 
(36% vs 43%, P = .0188). There was 53% physician adherence to 
the algorithm within 48 hours. As in PRORATA, the main rea-
son for nonadherence was concern about stopping antibiotics 
when the patient was not yet clinically stable. Although clinical 
outcomes were generally superior (mortality) or no different 
(hospital and ICU length of stay and requirement for additional 
courses of antibiotics within 28 days), 5% of the procalcitonin 
First Author 
(Year) 
[Reference]
Trial Name
Setting
(Country)
Number and Type of 
Infection PCT Algorithm Exclusion Criteria
Antibiotic 
Reduction 
Outcomes Clinical Outcomes
Shehabi (2014) 
[31]
ProGUARD
11 ICUs (Australia) 394 patients with 
suspected sepsis
Discontinuation only:
stop antibiotics if 
PCT <0.1 µg/L, 
or 0.1–0.25 and 
infection is highly 
unlikely, or subse-
quent PCT declines 
>90% from 
baseline (daily PCT 
measurements)
Antibiotics for surgical pro-
phylaxis or proven infec-
tion requiring >3 weeks 
of therapy, fungal or viral 
infections, immunosup-
pressed, cardiac surgery 
or trauma or heat stroke 
within 48 hours, medullary 
thyroid or small cell lung 
cancer, not expected to 
survive, pregnancy
Nonsignificant 
trend: median 
9 vs 11 days of 
antibiotic therapy 
(P = .58)
No difference (ventilation 
time, ICU and hospital 
LOS, hospital and 
90-day mortality)
de Jong (2016) 
[32]
SAPS
ICUs at 15 hospitals 
(Netherlands)
1546 patients with 
suspected or 
proven infection
Discontinuation only: 
stop antibiotics if 
PCT decreased 
to ≥80% of peak 
value, or ≤0.5 µg/L 
(daily PCT 
measurements)
Antibiotics for prophylaxis 
only or gut decontam-
ination, expected ICU 
stay <24 hours, severe 
immunosuppression, 
severe viral or parasitic or 
tuberculosis infections, 
moribund, chronic infec-
tion (eg, endocarditis)
Median antibiotic 
consumption of 
7.5 vs 9.3 daily 
defined doses (P 
< .0001), median 
treatment dura-
tion 5 vs 7 days 
(P < .0001)
Decreased 28-day mor-
tality (20% vs 25%, 
P = .0122) and 1-year 
mortality (36% vs 43%, 
P  = .0188). No differ-
ence in hospital and ICU 
LOS or requirement for 
additional antibiotics 
within 28 days. But 5% 
vs 3% rate of reinfec-
tion by same pathogen 
(P  = .0492)
Bloos
(2016) [50]
SISPCT
33 ICUs (Germany) 1089 patients with 
severe sepsis or 
septic shock
Discontinuation 
or “Alert”: PCT 
measured on 
days 0, 1, 4, 7, 10, 
and 14. On day 4: 
change antibiotics 
or intensify source 
control efforts if 
PCT not decreased 
by ≥50% from 
baseline value. 
Other days: stop 
antibiotics if PCT 
<1 or decreased 
by ≥50% from 
previous value. 
(2 × 2 factorial 
study design with 
sodium selenite 
administration and 
PCT arms)
Pregnancy or lactation, 
selenium intoxication, 
infections with long 
recommended treatment 
durations, immunocom-
promised, imminent death 
or treatment limitations
4.5% reduction 
in antibiotic 
exposure per 
1000 ICU days 
(823 days vs 
862 days) 
(P  = .02)
No difference in 28-day 
mortality (25.6% vs 
28.2%, P = .34), no dif-
ferences in procedures 
for infection source 
control or diagnosis
Abbreviations: ICU, intensive care unit; PCT, procalcitonin; LOS, length of stay; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment score. 
Table 2. Continued
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group required a second course of antibiotics for proven rein-
fection by the same pathogen, vs 3% in the standard care group 
(P = .0492).
Despite the mild increase in reinfection seen in the inter-
vention arm, the SAPS trial provides the strongest evidence 
to date that procalcitonin algorithms can be used to help 
safely decrease antibiotic exposure in critically ill patients, 
even when baseline antibiotic treatment courses are fairly 
short. More importantly, SAPS alleviated the concerning 
trend towards higher mortality seen in the PRORATA trial. 
Although the reasons for the lower mortality were not explic-
itly studied, the study authors speculated that high procal-
citonin levels may lead physicians to feel reassured about 
their initial diagnosis of sepsis, whereas low procalcitonin 
levels may lead physicians to seek noninfectious diagnoses 
at an earlier stage than they would otherwise and thus treat 
patients’ true causes of illness sooner [32]. In addition, anti-
biotic reduction may decrease adverse effects, selection of 
resistant pathogens, and C difficile.
LIMITATIONS AND AREAS FOR FUTURE RESEARCH
Despite the strength of evidence described above, there are 
several limitations to these studies that clinicians should be 
aware of before using procalcitonin in their own practice. First, 
in all procalcitonin-based trials, treatment group blinding 
is impossible, so the possibility of treatment bias cannot be 
ruled out. Randomized controlled trials are also accompanied 
by education and close guidance to physicians on how to apply 
the procalcitonin algorithms. Despite this, protocol adherence 
in the ICU-based trials has typically been approximately 50%. 
How closely physicians outside of clinical trials adhere to evi-
dence-based algorithms is unclear. Large, ideally prospective 
studies are thus needed to examine the way procalcitonin is 
being used as well as its impact in real-world situations. Future 
studies quantifying procalcitonin impact should also examine 
its effects on antibiotic-associated adverse reactions, C difficile 
infections, and antibiotic resistance. Cost-effectiveness should 
also be carefully evaluated; so far, however, several small stud-
ies do suggest a net positive benefit in terms of reduction of 
overall costs of care [33–35]. One retrospective propensi-
ty-matched observational study using a large US database 
also suggested that procalcitonin testing on ICU admission 
was associated with lower hospital and ICU length of stay and 
costs [36].
Second, the optimal strategy for implementing procalci-
tonin algorithms in hospitals to maximize compliance and 
its impact on antibiotic use, outcomes, and cost remains 
unknown. Procalcitonin algorithms may not be well under-
stood or trusted by front-line clinicians, and lessons can be 
learned from the literature showing that rapid diagnostics 
for bloodstream infections have greatest impact on patients 
and resource utilization when integrated with an antibiotic 
stewardship program that receives results in real-time and can 
intervene [37]. Furthermore, although the SAPS trial shows 
that procalcitonin can reduce antibiotic exposure when base-
line treatment courses are already short, it remains to be seen 
whether similar results can be achieved simply by shortening 
global duration of treatment recommendations and imple-
menting rigorous antibiotic stewardship programs. This is 
particularly relevant in light of recent randomized controlled 
trials and guidelines supporting shorter treatment courses for 
various infections [38–40].
Third, immunocompromised patients have generally been 
excluded from randomized controlled trials. However, evidence 
exists that procalcitonin is still a sensitive marker of sepsis in 
these patients [41]. Given that immunocompromised patients 
account for a substantial amount of antibiotic use, future 
research is required to determine whether procalcitonin algo-
rithms can help safely guide therapy in this patient population. 
Furthermore, optimal diagnostic cutoff points for sepsis may 
be higher in surgical versus medical patients with sepsis [42]. 
Surgical patients were a minority of cases in the large ICU-based 
trials, and it is unclear whether different algorithms should be 
applied in these patients. Other patient populations that have 
generally been excluded, but in whom guidance regarding anti-
biotic therapy duration would be valuable, include pregnant 
patients, patients with cystic fibrosis, and those with infections 
generally treated with prolonged antibiotic courses (such as 
osteomyelitis or endocarditis).
Fourth, although the procalcitonin cutoffs used for respira-
tory tract infections and ICU patients has been generally consist-
ent (0.25 µg/L and 0.5 µg/L, respectively), there have been slight 
variations in the algorithms in different studies. As demon-
strated by the ProGUARD study, where the procalcitonin cutoff 
level for discontinuing antibiotics was a conservative 0.1 µg/L, 
the benefit of procalcitonin may depend on what algorithm is 
used. At this point, however, it seems reasonable for hospitals 
to adopt the algorithms used in the largest studies for respira-
tory infections (ProHOSP) and ICU patients (PRORATA and 
SAPS). Future studies should aim (1) to explore the compar-
ative effectiveness of different algorithms to optimize the use 
of procalcitonin and (2) to demonstrate whether procalcitonin 
guidance is safe and effective for all types of suspected or proven 
infections in non-ICU patients, not just those with respiratory 
infections.
Finally, most of the trials have been conducted in Europe. 
Thus, the generalizability of these findings to the US pop-
ulation has not yet been clearly demonstrated. However, 
the Procalcitonin Antibiotic Consensus (ProACT) study, a 
US-based multicenter trial, is underway and hopefully will 
help close this particular knowledge gap [43]. This trial is sim-
ilar to the ProHOSP study and aims to study the effect of a 
procalcitonin algorithm in noncritically ill adult patients pre-
senting to the emergency department with lower respiratory 
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tract infections. A positive result from ProACT, and a study 
replicating SAPS in the United States, would undoubtedly go 
a long way in reassuring US-based practitioners about the 
safety and efficacy of procalcitonin for antibiotic guidance in 
the ICU.
PROCALCITONIN AS AN ALERT TOOL TO GUIDE 
ANTIBIOTIC ESCALATION
Although most of the ICU-based trials to date have focused 
on using procalcitonin as a tool to guide antibiotic discon-
tinuation, there has also been interest in using procalciton-
in-based screening to alert physicians to worsening sepsis. 
The Procalcitonin and Survival Study (PASS) was a rand-
omized controlled trial at 9 university hospitals in Denmark 
that enrolled 1200 adults within 24 hours of ICU admission, 
regardless of whether or not infection was initially suspected, 
and measured daily procalcitonin levels [44]. If procalcitonin 
levels were ≥1.0  µg/L and not decreasing at least 10% from 
prior day, clinicians were required to increase the spectrum 
of antibiotic coverage and/or intensify infection diagnos-
tic efforts. The study showed no benefit in 28-day mortality. 
Although the intervention increased the number of cultures 
taken and broad-spectrum antibiotic use, it did not improve 
time to appropriate antibiotics, except in patients with blood-
stream infections. There was evidence of harm with increased 
ICU length of stay and increased rates of mechanical ventila-
tion, vasopressor use, and renal injury.
SUMMARY AND RECOMMENDATIONS
Procalcitonin has been extensively studied as a biomarker of 
bacterial infection, and most studies suggest good but imper-
fect diagnostic performance. However, based on over a dozen 
randomized controlled trials, it can be a useful aid to guide 
antibiotic therapy in the following 2 scenarios (summarized in 
Figure 1): 
1. Non-critically ill patients with suspected or proven respira-
tory infection. Procalcitonin can be safely used at a cutoff of 
<0.25 µg/L to withhold antibiotics in stable, low-risk patients 
with suspected respiratory infections. If antibiotics are given, 
procalcitonin can help inform early discontinuation of anti-
biotics based on serial measurements, even in those with 
documented bacterial infections.
2. Critically ill patients with suspected infection/sepsis. Clinicians 
are understandably reluctant to withhold antibiotics when 
sepsis is first suspected in unstable patients, regardless of pro-
calcitonin levels, but serial procalcitonin measurements can 
be used at a cutoff of <0.5 µg/L or ≥80% decrease in peak level 
to help guide early antibiotic discontinuation once patients 
stabilize. Using procalcitonin in this fashion is safe, even in 
SUSPECTED RESPIRATORY INFECTION IN STABLE PATIENT SUSPECTED SEPSIS IN CRITICALLY ILL PATIENT
• Not critically ill or high-risk (e.g., CAP PSI ≥ IV / CURB 65 ≥ 2, COPD GOLD >111)
• Not severely immunocompromised (other than corticosteroids)
• No other concomitant infection requiring antibiotics
• Not severely immunocompromised (other than corticosteroids)
• Not on antibiotics for chronic bacterial infection (e.g. endocarditis, 
osteomyelitis) 
Obtain baseline PCT
but do not delay
antibiotics
Repeat PCT daily
Stop antibiotics when
PCT ≤ 0.5 pg/L or
decrease by ≥ 80%
from peak (and
patient clinically
improving)
PCT ≤ 0.25 µg/L
No Antibiotics
Recheck PCT 
after 6-24 hours 
if  hospitalized 
Notes:
•  If  PCT levels do not decline despite therapy, consider treatment failure (e.g., inadequate antibiotic therapy or source control)
• PCT algorithms apply to patients with clinically confirmed infections as well as those in whom infection was never proven
• PCT algorithms can be used as a clinical decision aid but should never override clinical judgment
PCT > 0.25 µg/L
Start Antibiotics
Repeat PCT on day 3 
and every other day 
if  still on antibiotics
Stop antibiotics when
PCT ≤ 0.25 µg/L (or
decrease by ≥ 80%
from peak if  initial
PCT >5 pg/L)
Figure 1. Suggested algorithms for using procalcitonin to guide antibiotic therapy in stable patients with respiratory infections and critically ill patients with sepsis. 
CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; PCT, procalcitonin; PSI, 
Pneumonia Severity Index.
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those with documented infections, and the largest trial to date 
(SAPS) suggests that it may even reduce mortality.
CONCLUSIONS
Clinicians must remember that false positives and negatives can 
occur with procalcitonin testing and that sepsis is a complex and 
heterogeneous syndrome. In most of the procalcitonin trials, 
overruling of the algorithm was allowed and in fact common in 
the ICU-based studies, underscoring the fact that procalcitonin 
should not replace clinical judgment. Clinicians should also be 
aware of the patients typically excluded from trials, particularly 
severely immunocompromised patients. However, when used 
properly as a clinical decision aid, the evidence is robust that 
procalcitonin can be a powerful antibiotic stewardship tool.
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